Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena
Pharmacology
[키워드] absence
acute respiratory syndrome
Anti-inflammatory
antibody
antimalarial
antiparasitic drug
Antiviral
arena
available data
benefit
candidate
Candidates
caused
cellular therapy
China
chloroquine/hydroxychloroquine
city
claimed
clinical manifestation
clinical trial
clinically
controls
convalescent plasma
coronavirus
Coronavirus disease 2019
COVID-19
criteria
cytokine
drug
Drug repurposing
effective
Epidemics
evaluated
Evidence
explain
Favipiravir
global pandemic
Guidance
identify
Immunotherapy
imperative
IMPROVE
in vitro activity
include
Inconclusive
initiation of treatment
interferon
investigational agent
Ivermectin
lack
MERS
Middle East
monoclonal
Natural killer cells
observational study
outcome
outcomes
pathology
pathophysiology
Patient
patient selection
Pneumonia
Population
Potential
Potential treatment
Prevent
progression
receptor
Remdesivir
Repurposed drug
responsible
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
small sample size
stem cell
syndrome
target
the disease
the patient
the timing
Therapeutic strategies
therapeutic strategy
therapy
Treatment
treatment guidelines
umifenovir
understanding
Understood
Vaccine
virus
Wuhan
[DOI] 10.3389/fphar.2020.585888 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.585888 PMC 바로가기 [Article Type] Pharmacology